Perspective Therapeutics (CATX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Perspective Therapeutics (CATX) is Neutral.

The composite score behind that read is -0.15, weighing +0.52 of bullish evidence against -0.31 bearish.

Perspective Therapeutics last closed at $2.57, -6.88% on the session.

Against the IVW growth benchmark the position is -7.80% over the forecast window.

The read is built from 12 underlying insights — 3 bullish and 9 bearish.

Agreement across those insights is 75%.

6 graded predictions for CATX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Perspective Therapeutics in the 20th percentile on return on equity, where 100 is best.

Perspective Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $315.06M.

StockMap tracks Perspective Therapeutics as the 193rd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Perspective Therapeutics ranks 107th of 344 in the group, against a group median of -0.21.